AT_1受体阻滞剂在心肌缺血/再灌注损伤的保护作用

Protective Effect of Angiotensin Ⅱ Type 1 Receptor Blocker in Myocardial Ischemia/Reperfusion Injury

急性心肌梗死最有效的治疗策略是溶栓或经皮冠状动脉介入性治疗再通梗阻血管,但心肌缺血/再灌注(I/R)损伤限制了经皮冠状动脉介入性治疗和溶栓的益处,提示需要进一步的辅助治疗。近年来,肾素-血管紧张素系统在心肌I/R中的作用日受关注,在心肌I/R过程中循环系统和心肌局部血管紧张素Ⅱ(AngⅡ)含量增加,参与I/R损伤的发展。动物模型研究证实,AngⅡ1型受体(AT1受体)阻滞剂对心肌I/R损伤具有保护作用。临床试验验证AT1受体阻滞剂在冠状动脉粥样硬化性心脏病患者是安全、有效的。

The most effective therapy for acute myocardial infarction is to recanalize the obstructive vessel by thrombolysis and percutaneous coronary interventional therapy,but the myocardial ischemia/reperfusion injury following them decreased the advantages of these two therapeutic methods,which needs further adjunctive therapy.In recent years,the effect of rennin-angiotonin system in myocardial I/R had attract more attention in recent years.The increased AngⅡ in circulation and local myocardium during myocardial I/R was involved in the development of I/R injury.Studies based on the animal experiments showed that angiotensin Ⅱ（AngⅡ）type 1 receptor（AT1R）blockers（ARB）had protective effect on the myocardial I/R injury.Clinical trials showed that the application of type 1 receptor（AT1R）blockers（ARB）in patients with atherosclerotic heart disease is safe and effective.